EUCTR2016-002259-11-ES进行中（未招募）1 期
A multicenter, open-label, single-arm, Phase IIIb trial to evaluate the effectiveness, safety, tolerability, usability and health economics resource utilization of Zalviso® for management of acute moderate to severe postoperative pain.
GRUNENTHAL PHARMA S.A.0 个研究点目标入组 200 人开始时间: 2016年7月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The patient has provided written informed consent and signed the IRB approved consent form.
- •2.The patient is an adult aged = 18 years old.
- •3.The patient is scheduled to undergo surgery, and is expected to remain hospitalized and have acute moderate to severe postoperative pain requiring parenteral opioids for at least 48 hours after surgery.
- •4.The patient has visual and cognitive ability to use the Zalviso® administration device correctly.
- •5.Treatment with Zalviso® according to the Summary of Product characteristics is appropriate for the patient.
- •6.Female patients of childbearing potential must be using an effective method of birth control.
- •Just before the start of treatment with Zalviso®, patients must fulfill all the following inclusion criteria to continue in the study:
- •1.The patient has had a pain intensity < 5 in the NRS at any time after the surgery but he/she has acute moderate to severe postoperative pain at the time of starting treatment with Zalviso®, defined as a pain intensity = 4 in the NRS.
- •2.Treatment with Zalviso® starts before midnight on the day of the surgery.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.The patient has hypersensitivity to the active substance or to any other ingredients of the sublingual tablet.
- •2.The patient has significant respiratory depression, that is, an arterial oxygen saturation by pulse oximetry (SpO2) that cannot be maintained at 95% or greater with or without supplemental oxygen.
- •3.The patient has current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure.
- •4.The patient has a medical condition that, in the Investigator’s opinion, could adversely impact the patient’s participation or safety, conduct of the study, or interfere with the pain assessments, including chronic pain or active infection.
- •5.The patient is deemed by the Investigator to be unable to use the Zalviso® administration device correctly.
- •6.The patient requires an additional scheduled surgical procedure within 72 hours of the surgery.
- •7.The patient has received surgical premedication with long-acting opioid analgesics.
- •8.The patient is receiving or has received monoamine oxidase inhibitors within 14 days before the study entry.
- •9.The patient has participated in a clinical trial of an investigational drug or device within 30 days of screening visit or is scheduled to receive an investigational product while participating in this study.
- •10.The patient is pregnant.
- •Just before the start of treatment with Zalviso®, patients must not meet any of the following exclusion criteria to continue in the study:
- •1.The patient is not awake, not breathing spontaneously or has a respiratory rate that is less than 8 breaths per minute or greater than 24 breaths per minute.
- •2.The patient is not able to answer questions and follow commands.
- •3.The patient is vomiting and not responsive to standard treatment
研究者
相似试验
进行中（未招募）
1 期
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemiaMedDRA version: 18.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864EUCTR2013-000087-29-BEF. Hoffmann- La Roche Ltd.950
进行中（未招募）
1 期
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemiaMedDRA version: 14.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864EUCTR2013-000087-29-SIF. Hoffmann- La Roche Ltd.972
进行中（未招募）
1 期
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemiaMedDRA version: 18.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864MedDRA version: 18.1 Level: LLT Classification code 10008977 Term: Chronic lymphocytic leukemia recurrent System Organ Class: 100000004864EUCTR2013-000087-29-SKF. Hoffmann- La Roche Ltd.972
进行中（未招募）
1 期
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864EUCTR2013-000087-29-PLF. Hoffmann- La Roche Ltd.950
进行中（未招募）
1 期
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemiaMedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10008977 Term: Chronic lymphocytic leukemia recurrent System Organ Class: 100000004864EUCTR2013-000087-29-SEF. Hoffmann- La Roche Ltd.972